picto We customize your future clinical

trials in Oncology with our innovative

Patient Derived Xenograft (PDX) models.

Founded in 2016, Oncofactory, a spin-off of the CNRS, is a science-driven biotech supporting pharmaceutical and biotechnology companies with innovative in vivo services to accompany their preclinical programs.

Oncofactory offers a unique technological platform with a core process for creating patient tumor replicas in avian embryos (AVI-PDX™) perfectly suited for preclinical evaluation of anticancer therapies.

Coupled with state-of-the-art 3D imaging and large-scale molecular analysis, our powerful process allows fast evaluation of therapy efficacy and deep characterization of mechanisms of action for biomarker discovery.



the efficacy of your
therapeutic candidates on representative samples of the population of patients

help you


in the design of combi-therapies through a dedicated program integrating analysis of tumor responses to the candidate therapy and characterization of candidate therapy-induced regulated signaling pathways



the mechanisms of action of your candidate therapies

identify biomakers


to stratify the population of patients, predict the resistance

pictoTake advantage
of our services for :

Direct in vivo evaluation of your molecules on patient tumor samples

exemples  Examples of cancer
types successfully…

Breast cancer
Prostate cancer
Pancreatic cancer
Lung cancer
Liver cancer
Germ Cell tumor

picto Process of studies by Oncofactory

Each project is managed by a unique scientific contact, in 3 steps:
• Exploratory meetings to precisely define the objectives and the specific requirements
(timetable, budget, scientific and technological issues)
• Customized studies with go/no-go decisions ensuring cost optimization and maximal
• Reporting with validated data, statistical analysis and images of each step of imaging
and quantification processes

The technology of Oncofactory is the fruit of many encounters, we could not name them all! That of the fields of oncology and developmental biology, which we know share many common mechanisms, that of two scientists passionate about the design of biological models, eager to exploit the expertise accumulated through years of fundamental research to develop innovative solutions for studying cancer, the one with many clinicians, professionals of the pharmaceutical industry, of technology transfer structures that have enlightened our choices, the one with Frédéric, with whom we share the same vision of the challenges that the development of new treatments and personalized medicine represent, in which we include the future of Oncofactory.
We wanted our technology to fully meet the expectations of the European Ethic Law. Achieving this goal by bringing in vivo solutions allowing all indispensable investigations while significantly limiting their impact on the animal is very rewarding.

We are fully confident that the innovative models of Oncofactory have their full place in the race to beat cancer.

Latest news

NLSDays 2023 (Nordic Life Science Days)

NLSDays 2023 (Nordic Life Science Days)

We are pleased to announce that the ERBC group, will be attending the 10th edition of the Nordic Life Science Days (NLSDays2023), that will be held in Copenhagen, Denmark, on November 29-30, 2023. Oncofactory is teaming up with Voxcan, both proud members of the ERBC...

Festival of Biologics 2023

Festival of Biologics 2023

Come and meet us at FOB 23 from 10 to 12 October, Basel. We are pleased to announce our participation in the upcoming Festival of Biologics 2023 (FOB) from October 10th to 12th in Basel, Switzerland. Oncofactory is teaming up with Voxcan, both proud members of the...

Follicular lymphoma AVI-PDX models to predict the response to RCHOP

Follicular lymphoma AVI-PDX models to predict the response to RCHOP

Follicular lymphoma AVI-PDX models to predict the response to RCHOPWe are thrilled to communicate the preliminary data of our ongoing FLINOVO program performed in collaboration with Dr. Pierre Sujobert (HCL, Centre hospitalier Lyon Sud and CIRI/Lyon 1 University), and...